Moderna, Inc.

MRNA Nasdaq CIK: 0001682852

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 325 BINNEY STREET, CAMBRIDGE, MA, 02142
Mailing Address 325 BINNEY STREET, CAMBRIDGE, MA, 02142
Phone 6177146500
Fiscal Year End 1231
EIN 813467528

Financial Overview

FY2024

$18.43B
Total Assets
$3.21B
Cash & Equivalents
$21.26
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
8-K Current report of material events February 13, 2026 View on SEC
8-K Current report of material events February 11, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 9, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 6, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 5, 2026 View on SEC
8-K Current report of material events January 12, 2026 View on SEC

Material Events

8-K Other February 11, 2026
High Impact
  • Moderna's strategic goal to diversify its product portfolio beyond the COVID-19 vaccine.
  • Targeting the multi-billion dollar seasonal flu vaccine market with mRNA-1010.
View Analysis

Insider Trading

SELL 2 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.